PUBLISHER: TechNavio | PRODUCT CODE: 1719492
PUBLISHER: TechNavio | PRODUCT CODE: 1719492
The neurodegenerative diseases therapeutics market is forecasted to grow by USD 24852.2 mn during 2024-2029, accelerating at a CAGR of 9.1% during the forecast period. The report on the neurodegenerative diseases therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by strong drug development pipeline, high research funding on neurodegenerative diseases, and availability of highly sensitive diagnostic modalities.
Market Scope | |
---|---|
Base Year | 2025 |
End Year | 2029 |
Series Year | 2025-2029 |
Growth Momentum | Accelerate |
YOY 2025 | 8% |
CAGR | 9.1% |
Incremental Value | $24852.2 mn |
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
Technavio's neurodegenerative diseases therapeutics market is segmented as below:
By Indication
By Drug Class
By Route Of Administration
By End-user
By Geographical Landscape
This study identifies the increase in aging population as one of the prime reasons driving the neurodegenerative diseases therapeutics market growth during the next few years. Also, improved understanding of genetic basis and molecular pathology of neurodegenerative diseases and high economic burden will lead to sizable demand in the market.
The report on the neurodegenerative diseases therapeutics market covers the following areas:
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading neurodegenerative diseases therapeutics market vendors that include AB Science SA, AbbVie Inc., Acadia Pharmaceuticals Inc., AstraZeneca Plc, Biogen Inc., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, H Lundbeck AS, Johnson and Johnson Services Inc., Merck and Co. Inc., Mitsubishi Chemical Corp., Novartis AG, Pfizer Inc., Sanofi SA, and Teva Pharmaceutical Industries Ltd.. Also, the neurodegenerative diseases therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Exhibits: